



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
OCT 02 2001
TECH CENTER 1600/2900
GAL 1623
#13

Applicants: Gosselin et al.

Serial No.: 09/371,747

Group Art Unit: 1623

Filed: August 8, 1999

Examiner: L. Eric Crane

For: β -L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B

Assistant Commissioner for Patents
Washington, DC 20231

September 24, 2001

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


MAIL ROOM RETURN

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publication listed on the accompanying Form PTO-1449. A copy of the listed reference is enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

Please charge \$180.00 and any additional fees under 37 CFR 1.97(c)(2) for this submission to Deposit Account No. 11-0980.

Respectfully submitted,


Josephine Young
Registration No. 48,308

KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-4600 (Telephone)
404-572-5145 (Facsimile)


TECH CENTER 1600/2900

OCT 02 2001

RECEIVED

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Josephine Young

Date: September 24, 2001